Ceramide metabolism has emerged as a potential target for anticancer therapy. Here, the potential usefulness of two novel synthetic ceramide analogs as anti-leukemic drugs was investigated. Compounds AD2646 and AD2687 were able to dose-and time-dependently decrease the viability of Jurkat leukemic cells. This was accompanied by an accumulation of endogenous ceramide owing to perturbed ceramide metabolism. Cytotoxicity involved caspase activation but also necrotic-like features, as evidenced by phosphatidylserine externalization, membrane permeability, hypodiploidy, caspase processing and only partial protection from cell death by a pan-caspase inhibitor. Ceramide analogs also induced cell death in Jurkat mutants that are deficient in cell death signaling proteins, including FADD, caspase-8 and 10, and RIP. While overexpression of Bcl-xL did not suppress ceramide accumulation, it conferred robust protection from caspase activation and cell death. Altogether, these novel ceramide analogs are able to kill leukemic cells through distinct pathways implicating caspase activation and mitochondrial events, and represent a new group of bioactive molecules with potential applications in anticancer therapy.
Introduction
Sphingolipids are now recognized as a novel class of biomodulators that can regulate a wide spectrum of cellular responses, including cell death. In particular, sphingomyelin (SM) metabolites, such as ceramide and sphingosine 1-phosphate, behave as tumor-suppressor or tumor-promoting lipid mediators, respectively. Recent interest has thus emerged on the potential use of ceramide in the treatment of several pathological conditions, and notably in cancer (for a recent review, see Ogretmen and Hannun 1 ). Since the pioneering work by Obeid and Hannun on the induction of apoptosis of leukemic cells by exogenous ceramide, 2 numerous studies have established the cytotoxic effect of this lipid. Not only can stress agents, including cytokines, chemotherapeutic drugs, ionizing radiation and photodynamic therapy, promote the production and intracellular accumulation of ceramide before the onset of apoptosis, but also addition of exogenous, either short-chain or long-chain (natural) ceramides to a variety of tumor or leukemia cell types lead to cell death. 1 In addition, genetic or pharmacological manipulation of ceramide-metabolizing enzymes results in elevation of intracellular concentration of ceramide and subsequent cell death.
As sphingolipids can affect many aspects of cancer pathogenesis, and because defects of ceramide production have been observed in tumor cells and multidrug resistant cells, 1 anticancer therapeutic strategies aiming at restoring a normal metabolism or the accumulation of ceramide have been recently developed. 3, 4 Owing to the complexity of ceramide metabolism, interfering with the enzymatic biosynthesis or degradation of ceramide, or its conversion to other, non-antiproliferative sphingolipids, is likely to require a multi-target approach. This concept, also justified by the fact that cancer cells could adapt themselves to a single alteration, is illustrated by the recent use of a poly-drug chemotherapy aiming at blocking simultaneously different pathways of ceramide metabolism. 5 Whereas this approach needs to target several pathways concomitantly, another (complementary) strategy is the administration of an exogenous ceramide analog or mimetic to directly induce cancer cell death. Addition of synthetic short-chain ceramides, ceramines, C16-or C18-serinols, cationic ceramides as well as some other analogs was reported to mimic ceramide in inducing apoptosis in various cancer or leukemia cell lines, and, in some instances, to reduce the mass of xenografted tumors. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These observations have emphasized the potential usefulness of developing novel, ceramide-based chemotherapeutic agents for anticancer treatment.
In this study, we further investigated the cytotoxic properties of novel ceramide analogs, AD2646 and AD2687, that we recently synthesized. 16 Their ability to kill leukemic T cells, and the cell death signaling pathways they trigger were investigated. We show that these ceramide analogs affect intracellular sphingolipid metabolism, elevate ceramide content, and promote a Bcl-xL-inhibitable cell death.
Materials and methods

Materials and ceramide analogs
The procedures for synthesis of ceramide analogs AD2646 and AD2687, and Bodipy-C3-ceramide, as well as the structures of these compounds (see also Figure 1 ), have been reported. 16 zVAD-fmk was purchased from Bachem (Voisins-Le-Bretonneux, France). Polyclonal anti-caspase-8 was a kind gift from Dr G Cohen (Leicester, UK). Polyclonal anti-caspase-3 was obtained from Dako (Trappes, France). Polyclonal anti-PARP and anti-caspase-9 were from Cell Signaling Technology (SaintQuentin-en-Yvelines, France). Monoclonal anti-b-actin was from Sigma (Saint-Quentin Fallavier, France). Human recombinant FasL was obtained from Abcys (Paris, France).
Cell culture
Human T-cell leukemic Jurkat cells were from ATCC. Jurkat clones, transfected with an empty vector (Jurkat/neo) or with a Bcl-xL expressing vector (Jurkat-Bcl-xL), 17 were kindly provided by Dr O Cuvillier (INSERM U.466, Toulouse, France). Jurkat clone I9-2e, deficient for caspase-8 and having a low caspase-10 level, has previously been described. 18 Jurkat cells were grown in RPMI 1640 medium containing Glutamax and 10% heat-inactivated FCS (Invitrogen, Cergy-Pontoise, France, or Kibbutz Beth Ha'Emek, Israel). When testing the effects of ceramide analogs on cells, ceramide analogs were added to the cells as ethanolic or DMSO solutions; the concentration of the solvent did not exceed 0.5% for ethanol and 0.1% for DMSO.
Cell viability, flow cytometry and morphological analyses
Cell viability was assessed using the MTT test. Cell morphology was analyzed using Syto 13 and propidium iodide (PI), Ceramide analogs trigger Jurkat cell death T Granot et al and phosphatidylserine externalization was monitored as described. 18 
Determination of caspase activity
Effector caspase activity was measured on cell lysates using the fluorogenic substrate Ac-Asp-Glu-Val-Asp-aminomethylcoumarin (DEVD-AMC; Bachem) as described. 19 Alternatively, caspase cleavage was examined by Western blot.
Glucosylceramide synthase and sphingomyelin synthase assays
Jurkat cells were incubated in the absence of FCS with the analogs for varying times. For glucosylceramide (GlcCer) and SM synthase assays, one hour after the beginning of the experiment, Bodipy-C3-ceramide (2.5 mM) was added to the cells. At the end of the experiment, the lipids were extracted and separated as described. 16 
Ceramide quantification
Lipids were extracted with chloroform/methanol from the cell lysates prepared for DEVDase assay. Ceramide content was determined using E. coli diacylglycerol kinase (kindly provided by Drs D Perry and YA Hannun, Charleston, SC) and [
32 P]g-ATP (6000 Ci/mmol; Perkin-Elmer) as previously reported. 20 Of note, the ceramide analogs AD2646 and AD2687 did not produce phosphorylated forms that could interfere with the ceramide assay.
Other determinations
Protein content was determined using bicinchoninic acid or the Bradford method (Biorad).
Statistical studies
Results are expressed as means7s.d. or s.e.m., and are averages of at least three values per experiment. Mean values were compared using the Student's t-test. Differences were considered statistically significant when Po0.05 (as indicated by an asterisk on the figures).
Results
Ceramide analogs induce Jurkat cell death
Based on initial observations on leukemic HL-60 cells, 16 we investigated the potential cytotoxic effect of novel synthetic ceramide analogs on the human leukemia Jurkat T-cell line. As illustrated in Figure 1a and b, AD2646 and AD2687 compounds exhibited a dose-dependent cytotoxic action that was enhanced by decreasing the cell density. The AD2687 analog displayed a higher cytotoxicity than the AD2646 compound ( Figure 1c ). Reduction in cell viability was observed even after short-term (4 h) incubation (data not shown), with EC50 values approximating 15 and 40 mM for AD2687 and AD2646, respectively. We then compared the cytotoxicity of these novel analogs to that of a previously described compound, AD2557 (also called B13). 9 As shown in Figure 1d , AD2646 that has an amine (-R-CH 2 -NH-) bond, was much more toxic than AD2557, which has an amide (-R-CO-NH-) bond. Addition of FCS (10%) to the incubation medium resulted in an increased EC50 for all compounds (data not shown).
Ceramide analogs impair ceramide metabolism and trigger ceramide accumulation
Because of their previously reported effects on GlcCer and SM biosynthesis in HL-60 cells, 16 AD2646 and AD2687 were tested for their potential inhibitory action on sphingolipid metabolism in Jurkat cells. As observed after incubating cells with a fluorescent ceramide substrate, both compounds inhibited GlcCer (Figure 2a ) and SM (Figure 2b ) syntheses, the latter being more susceptible to AD2687 than AD2646. Inhibition of Ceramide analogs trigger Jurkat cell death T Granot et al these biosynthetic pathways was accompanied by a timedependent accumulation of ceramide, which was detectable as early as after 2 h incubation with the analogs (Figure 2c ). This accumulation might also result from inhibition of acid and/or neutral ceramidase activity (see Supplementary Information and He et al 21 ).
Ceramide analogs kill Jurkat cells through caspase-dependent and -independent pathways
To further characterize the cytotoxic effect of ceramide analogs, we first examined their impact on Jurkat cell permeability and phosphatidylserine externalization (Figure 3 Ceramide
, and also of PI-positive cells (Figure 3b) . Appearance of these populations was dose-dependent, as indicated by the dose-dependent decrease in the proportion of annexin-V-and PI-negative cells (Figure 3a) . These changes were accompanied by morphological alterations characteristic for apoptotic cell death, for example, nuclear condensation and fragmentation (Figure 3c) .
We then tested the contribution of caspases and classical apoptosis to the ceramide analog-induced Jurkat cell death. Preincubation of the cells with the broad-spectrum caspase inhibitor, z-VAD-fmk, resulted in a significant reduction of the annexin-V-positive and PI-negative cell population, but little or no change in the proportion of PI-positive cells (Figure 3b ). This was reflected by small (for AD2646) or partial (for AD2687) changes in the overall cell viability as estimated by the proportion of doubly negative cells (Figure 3a) or by MTT assay (data not shown). Whereas z-VAD-fmk efficiently prevented nuclear fragmentation, it did not reduce membrane permeability and necrotic-like alterations (Figure 3c ). Ceramide analogs also led to an increased proportion of hypodiploid cells, an effect that was considerably, but not completely in the case of AD2687, attenuated by co-treatment with z-VAD-fmk (see Supplementary Information). Altogether, these observations indicate that ceramide analogs impair Jurkat cell viability through distinct mechanisms.
Ceramide analogs efficiently kill Jurkat cells harboring defects in the apoptotic cascade but not Bcl-xLoverexpressing cells
Because ceramide analog-induced cytotoxicity was partially mediated by an apoptotic mechanism, we examined the sensitivity of various Jurkat cell mutants to these analogs. Ceramide analog-induced cell death was not impaired in FADD-, RIP-or caspase-8 and -10-deficient cells, which are resistant to FasL-induced cell death (see Supplementary  Information) . This strongly suggests that the cytotoxic pathway activated by the ceramide analogs is not regulated by the death receptor adaptor FADD nor the initiator caspases-8 and -10. To test whether caspases were activated upon treatment with these ceramide analogs, we analyzed caspase activation by Western blotting. As illustrated in Figure 4a , AD2646 and AD2687 triggered the cleavage of caspase-8, -9 and -3, as well as the caspase substrate PARP. The caspase-3-like activity towards a synthetic tetrapeptide substrate peaked at 4 h incubation with both analogs (Figure 4b ). These events were also observed in I9-2e Jurkat cells (Figure 4a ), a variant of caspase-8-deficient cell line exhibiting a low caspase-10 expression, which is resistant to FasL-induced cell death, 18 indicating that the analogs activate caspase-3 independently or downstream of initiator caspases. In contrast, FasLinduced caspase activation was abrogated in I9-2e cells (Figure 4a) .
Finally, to test the potential implication of mitochondria in ceramide analog-induced cell death, we studied the effect of AD2646 and AD2687 on Jurkat cells stably overexpressing the anti-apoptotic, mitochondrial protein, Bcl-xL. 17 Bcl-xL overexpression suppressed ceramide analog-induced caspase activation ( Figure 5a ) and strongly attenuated cell death (Figure 5b) . However, overexpression of Bcl-xL did not completely abrogate ceramide accumulation (Figure 5c ) indicating that generation of ceramide occurred upstream of mitochondria and is not the trivial consequence of cell demise.
Discussion
Ceramide metabolism is currently viewed as an attractive target for anticancer therapy. 1, 4, 5, 22 This view is supported by the following arguments. First, various commonly used anticancer drugs and ionizing radiation elicit ceramide accumulation in tumor cells. Second, chemo-or radio-resistant cancer/leukemia cells exhibit defects in ceramide production, and restoration of the ability to generate ceramide or administration of exogenous ceramide leads to resensitization to cell death. Third, inhibition of intracellular ceramide accumulation results in resistance of cancer/leukemia cells to stress agents. This has been accomplished either by blocking SM breakdown or de novo ceramide biosynthesis using pharmacological inhibitors or genetic approaches including antisense oligodesoxynucleotides or RNA interference. Alternatively, reducing ceramide levels by enhancing its conversion to other sphingolipids such as GlcCer (via overexpression of glucosylceramide synthase) can promote chemoresistance. 5 Reciprocally, blocking ceramide degradation through inhibition of ceramidase or ceramide conversion by inhibition of SM or GlcCer synthases can sensitize cells to anticancer drug-induced cell death (see Ogretmen and Hannun 1 ). 
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Whereas manipulation of intracellular ceramide concentrations by interfering with its metabolizing enzymes is likely to require multiple intervention (as proposed by the so-called polydrug therapy approach), 5 addition of ceramide analogs that can mimic the antiproliferative effects of endogenous ceramide represents an alternative strategy for killing tumor cells. With the latter aim, various cell-permeant, structurally related ceramide analogs have been synthesized which indeed displayed cytotoxicity. Besides short-chain (C2, C6 or C8) ceramides, which penetrate cells more easily than natural long-chain ceramides and kill leukemic or lymphoma cells, 2, 7, 23, 24 ceramide analogs having an amine instead of an amide bond proved to be pro-apoptotic for U937 leukemic cells. 6 Another type of structural analog, FS-5, having a short sphingoid moiety, induced apoptosis of Molt-4 leukemic cells.
25 N-acylated derivatives of serinol also caused apoptosis of neuroblastoma or breast cancer cells. 8, 26 Further analogs exhibited cytotoxicity against cancer cells, including compounds containing a thiouracil ring, 27 benzene, 28 or 4,6-diene-ceramides. 14 In addition to the numerous effects reported on different cell culture models, several ceramide analogs proved to be effective in vivo, some of them having been administered as liposomes. 29 Treatment (by intraperitoneal injection) of mice with B13 led to reduction or even suppression of liver metastases of colon cancer. 9 The same analog could sensitize xenografted prostate tumors to radiation and reduce tumor volume. 13 More recently, N-oleoyl-serinol has been shown to prevent teratoma formation after transplantation into mouse brain. 12 These observations emphasize the usefulness of developing ceramide mimics as potential antitumor agents.
We have synthesized new metabolically stable compounds that share structural homology with ceramide. Despite comparable uptake by cells, these non-natural analogs display higher toxicity than short-chain ceramides or previously synthesized related compounds (such as B13/AD2557). There is not yet clear-cut structure-activity relationship. However, in analogy with previously developed cytotoxic analogs, these compounds contain an allylic hydroxyl group in C3, which has been proposed to be important in mediating their effects, possibly at the mitochondrial levels by generation of reactive oxygen species. 5 The presence of an aromatic ring in our analogs, as well as in B13, may also contribute to the biological action. However, the amide linkage (present in B13 but absent in AD2646) seems dispensable. 6 Replacing this ring by a 4,6-diene also resulted in a potent cytotoxic effect.
14 Moreover, the toxicity of AD2687 might be related to its analogy with trimethylsphingosine, a sphingolipid derivative previously reported to be cytotoxic. 30 The present study demonstrates that these new ceramide derivatives induce leukemic cell death by typical apoptosis as well as by other types of cell death. Not only was caspase activity stimulated, leading to DNA fragmentation, but also inhibition of caspase activity by synthetic peptide inhibitors or overexpression of anti-apoptotic proteins could protect from cell death. In agreement with previous studies also showing protection by Bcl-2 overexpression, 24, 25 our observations suggest that the ceramide analogs activate the apoptotic machinery upstream of the mitochondria. In addition, as reported for short-chain ceramides, 11, [31] [32] [33] [34] the ceramide analogs trigger a non-apoptotic form of cell death because caspase inhibitors did not completely block membrane permeability alterations, phosphatidylserine externalization, morphological changes and cell death.
The molecular mechanism(s) of action of ceramide mimics still remain(s) poorly elucidated. Several hypotheses have been proposed, including activation of serine-threonine kinases, for example, PKCz, 8, 12 mitochondrial events, that is, disruption of mitochondrial membrane potential, production of reactive oxygen species, and cytochrome c release, 14 drop in glutathione levels 13 or Rb dephosphorylation. 7 Positively charged ceramides also appear to trigger mitochondrial permeabilization. 15 One of the putative mechanisms that underlie these alterations is the increased endogenous ceramide level. Sustained elevation of ceramide was observed after treatment with our analogs: a finding also described with other ceramide mimics, including Nacylated-serinol, B13 and diene-ceramides. 8, 9, 14 Interestingly, the present study shows that ceramide accumulation occurs upstream of the mitochondrial events since, in contrast to execution of the cell death program, it was not suppressed by Bcl-xL overexpression. Several mechanisms could account for ceramide elevation : inhibition of SM and GlcCer synthases (present study), inhibition of ceramide degradation by cerami- Ceramide analogs trigger Jurkat cell death T Granot et al dase, 9 or ceramide-induced 'self-accumulation'. 35, 36 In accordance with these hypotheses, other compounds such as PPMP or D609, which inhibit ceramide conversion to GlcCer or SM, also trigger cell death. 37, 38 Inhibition of acid ceramidase activity by AD2646 has recently been reported; 21 it is, however, unlikely that this mechanism solely accounts for the cytotoxic effect of AD2646 and AD2687 because control and Farber (acid ceramidase-deficient) lymphoblasts were equally sensitive to these analogs (data not shown).
Altogether, these observations support the feasibility of a novel therapeutic approach based on manipulation of ceramide metabolism to kill tumor cells, that could synergize with classical antitumor agents (e.g. as shown with Safingol 37, 39 ). They also emphasize the need for a better understanding of the mode of action of these sphingolipid analogs, and for developing even more active and/or selective derivatives.
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